Condition: Atrial Fibrillation · Stroke · Sponsor: University of Aarhus
Atrial fibrillation (AF) is progressively common, and increases the risk of stroke five-fold. Oral anticoagulation is the mainstay therapy; however, it increases the risk of bleeding. Moreover, 30% with AF and at risk of stroke are not in relevant anticoagulation. The randomized PROTECT-AF trial has demonstrated the superiority of left atrial appendage occlusion (LAAO) as compared to warfarin for prevention of the combined endpoint of stroke, major bleeding and cardiovascular mortality. However, studies comparing LAAO to therapy with novel oral anticoagulants (NOAC) have not been carried out. This study aims to assess the effect of left atrial appendage occlusion (LAAO) to reduce the incidence of stroke, systemic embolism, major bleeding and all-cause mortality in patients with atrial fibrillation (AF) and a prior ischemic stroke or transient ischemic attack (TIA).
This description comes directly from the study's public registry record.
Kasper Korsholm, MD · 004578452254 · kasperkorsholm@clin.au.dk
Always discuss trial participation with your own doctor first.
| Aarhus University Hospital | Aarhus, Central Jutland, Denmark | Recruiting |
| Odense University Hospital | Odense, Region Syddanmark, Denmark | Active Not Recruiting |
| Aalborg University Hospital | Aalborg, The North Denmark Region, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Not Yet Recruiting |
| Regional Hospital West Jutland | Holstebro, Denmark | Recruiting |
| Helsinki University Central Hospital | Helsinki, Finland | Recruiting |
| Oulu University Hospital | Oulu, Finland | Withdrawn |
| Turku University Hospital | Turku, Finland | Not Yet Recruiting |
| Jena University Hospital | Jena, Germany | Recruiting |
| Haukeland University Hospital | Bergen, Norway | Recruiting |
| Oslo University Hospital | Oslo, Norway | Recruiting |
| Trondheim University Hospital | Trondheim, Norway | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03642509